利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.014 秒)

    Protein having cell growth-stimulating and macrophage chemotactic actions, preparative method therefor and use thereof
    1.
    发明授权
    Protein having cell growth-stimulating and macrophage chemotactic actions, preparative method therefor and use thereof 失效
    具有细胞生长刺激和巨噬细胞趋化作用的蛋白质，其制备方法及其用途

    公开(公告)号：US5464818A

    公开(公告)日：1995-11-07

    申请号：US365820

    申请日：1994-12-29

    申请人： Tadashi Yamaguchi ,  Hiroshi Uesaka ,  Kazuo Watanabe ,  Juichi Awaya

    发明人： Tadashi Yamaguchi ,  Hiroshi Uesaka ,  Kazuo Watanabe ,  Juichi Awaya

    IPC分类号： A61K38/00 ,  C07K14/33 ,  C07K14/475 ,  C12N9/52 ,  C12P21/00 ,  A61K38/02

    CPC分类号： C07K14/33 ,  C07K14/475 ,  C12N9/52 ,  A61K38/00 ,  Y10S435/842

    摘要： There are described a novel protein derived from Clostridium perfringens FERM BP-4584 method of obtaining the same and use thereof as an effective ingredient for treating wounds and ulcers. The protein has a molecular weight of 420,000.+-.40,000 by a GPC, isoelectric point of 4.8, and consists of a single subunit having a molecular weight of 130,000.+-.20,000 by a SDS-polyacrylamide gel electrophoresis, and shows cell growth-stimulating activity as well as macrophage chemotactic action. The protein can be extracted and separated by conventional techniques for obtaining a protein from general microorganisms, by taking an inhibition of decomposition into consideration, since the protein is not so stable.

    摘要翻译： 描述了产生产气荚膜梭菌FERM BP-4584的新型蛋白质，其获得相同的作用和用作治疗伤口和溃疡的有效成分。 该蛋白质通过GPC，等电点为4.8，分子量为420,000 +/- 40,000，通过SDS-聚丙烯酰胺凝胶电泳由分子量为130,000 +/- 20,000的单个亚基组成，并显示出细胞生长 - 刺激活性以及巨噬细胞趋化作用。 蛋白质可以通过常规技术提取和分离，以通过考虑抑制分解来获得一般微生物的蛋白质，因为蛋白质不是如此稳定。

    Method of predicting threatened premature delivery in a pregnant woman
    2.
    发明授权
    Method of predicting threatened premature delivery in a pregnant woman 失效
    孕妇威胁性早产的预测方法

    公开(公告)号：US5290679A

    公开(公告)日：1994-03-01

    申请号：US898681

    申请日：1992-06-15

    申请人： Toshihiko Terao ,  Naohiro Kanayama ,  Akihiro Morioka ,  Yoshika Yasuda ,  Masami Kamiya ,  Juichi Awaya ,  Masayasu Kurono ,  Kiichi Sawai

    发明人： Toshihiko Terao ,  Naohiro Kanayama ,  Akihiro Morioka ,  Yoshika Yasuda ,  Masami Kamiya ,  Juichi Awaya ,  Masayasu Kurono ,  Kiichi Sawai

    IPC分类号： A61K49/00 ,  G01N33/573 ,  C12Q1/00 ,  C12Q1/37

    CPC分类号： G01N33/573

    摘要： Even when the specimen contains human granulocyte elastase in the form of a mixture of free elastase with an elastase-inhibitor complex or complexes, the present invention enables the total quantity of elastase in that specimen to be precisely detected. The inhibitor is added to free elastase to convert it into an elastase-inhibitor complex, whereby the quantity of elastase can be measured by immunoassay as the total amount including the previously existing elastase-inhibitor complex. It is possible to precisely measure the total amount of elastase in mucus collected from the cervical canal of a pregnant woman, sputum or a rinsed solution of bronchovesicular lavage in which free elastase is mixed with an elastase-inhibitor complex. It is thus possible to predict and prevent threatened premature delivery, premature delivery or premature rupture of membranes by immunoassay of mucus collected from the cervical canal of a pregnant woman, to make a diagnosis of chronic or repetitive airway infections and pulmonary emphysema based on chronic respiratory diseases by immunoassay of sputum and a rinsed solution of bronchovesicular lavage and to make a diagnosis of urinary tract infections by immunoassay of urine.

    摘要翻译： 即使样品含有游离弹性蛋白酶与弹性蛋白酶抑制剂复合物或复合物的混合物形式的人粒细胞弹性蛋白酶，本发明能够精确地检测该样本中弹性蛋白酶的总量。 将抑制剂加入到游离弹性蛋白酶中以将其转化成弹性蛋白酶抑制剂复合物，由此弹性蛋白酶的量可以通过免疫测定来测量，包括先前存在的弹性蛋白酶抑制剂复合物的总量。 可以精确测量从孕妇，痰液或冲洗的支气管泡灌洗液的宫颈管中收集的弹性蛋白酶的总量，其中游离弹性蛋白酶与弹性蛋白酶抑制剂复合物混合。 因此，可以通过从孕妇的宫颈管收集的粘液的免疫测定来预测和预防受威胁的早产，早产或过早破裂，以诊断慢性或重复性气道感染和基于慢性呼吸的肺气肿 通过免疫测定痰液的疾病和支气管泡灌洗液的清洗溶液，并通过免疫测定尿液来诊断尿路感染。

    Antibiotic composition
    3.
    发明授权
    Antibiotic composition 失效
    抗生素组成

    公开(公告)号：US4226879A

    公开(公告)日：1980-10-07

    申请号：US939102

    申请日：1978-09-01

    申请人： Satoshi Omura ,  Chiaki Kitao ,  Akira Nakagawa ,  Haruo Tanaka ,  Juichi Awaya ,  Ruiko Oiwa

    发明人： Satoshi Omura ,  Chiaki Kitao ,  Akira Nakagawa ,  Haruo Tanaka ,  Juichi Awaya ,  Ruiko Oiwa

    IPC分类号： A23K20/195 ,  A61K31/335 ,  A61K35/00 ,  C07D303/06

    CPC分类号： A23K20/195

    摘要： The present invention relates to a new composition designated as AM-1042 or asukamycin. AM-1042 has an antibiotic activity upon Gram-positive bacteria and Eimeria, and its acute toxicity (LD.sub.50 ' ip.) in mice was 48.5 mg./kg. AM-1042 has an excellent therapeutical effect on various infectious diseases caused by a parasite of Gram-positive bacteria and Eimeria. AM-1042 has been confirmed to be distinguishable from known antibiotics such as e.g. amicetin B, azomycin and manumycin. AM-1042 is produced by fermentation of a microorganism belonging to the genus Streptomyces and capable of producing AM-1042. A composition capable of preventing and curing coccidiosis of poultry containing AM-1042 as active ingredient.

    摘要翻译： 本发明涉及一种称为AM-1042或无菌素的新组合物。 AM-1042对革兰氏阳性菌和艾美球虫具有抗菌活性，其在小鼠中的急性毒性（LD50'ip。）为48.5mg./kg。 AM-1042对由革兰氏阳性菌和艾美球虫寄生虫引起的各种感染性疾病具有极好的治疗作用。 已证实AM-1042可与已知的抗生素区别，例如： amicetin B，azomycin和manumycin。 AM-1042是通过发酵属于链霉菌属的微生物并产生AM-1042产生的。 一种能够预防和治疗含有AM-1042作为活性成分的家禽的球虫病的组合物。

    Compound nanaomycin A and derivatives thereof and a process for producing the same
    6.
    发明授权
    Compound nanaomycin A and derivatives thereof and a process for producing the same 失效
    复方纳诺霉素A及其衍生物及其制备方法

    公开(公告)号：US4324728A

    公开(公告)日：1982-04-13

    申请号：US47451

    申请日：1979-06-11

    申请人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    发明人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    IPC分类号： C07D311/92 ,  A61K31/35 ,  A61K31/352 ,  A61P31/04 ,  C12P7/66 ,  C12P17/06

    CPC分类号： C12R1/465 ,  C12P17/06

    摘要： The present invention relates to new compound nanaomycin A and derivatives thereof represented by general formula: ##STR1## in which (a) R is H and R' is OH (nanaomycin A),(b) R is H and R' is NH.sub.2 (nanaomycin C),(c) R is COCH.sub.3 and R' is OH (acetylnanaomycin A), and(d) R is H and R' is OCH.sub.3 (nanaomycin A methyl ester).Nanaomycin A is a new compound of quinone type and its acute toxicity (LD.sub.50, intra-penetrial injection) in mice is 28.2 mg/Kg. Nanaomycin A and derivatives thereof are active on Gram-positive bacteria, trichophyton and mycoplasma and are useful as a medicament for humans and animals. Nanaomycins A and C are produced by culturing a nanaomycin-producing strain belonging to the genus Streptomyces aerobically in a medium to accumulate nanaomycins A and C in the cultured broths. The derivatives acetylnanaomycin A and nanaomycin A methyl ester have similar properties to those of nanaomycin A.

    摘要翻译： 本发明涉及由以下通式表示的新化合物纳那霉素A及其衍生物：其中（a）R是H，R'是OH（纳那霉素A），（b）R是H和R' 是NH2（纳那霉素C），（c）R是COCH 3，R'是OH（乙酰氨基霉素A），和（d）R是H，R'是OCH 3（纳诺霉素A甲酯）。 Nanaomycin A是醌类的新化合物，其在小鼠中的急性毒性（LD50，内渗注射）为28.2mg / Kg。 纳诺霉素A及其衍生物对革兰氏阳性菌，毛毛虫和支原体具有活性，可用作人和动物的药物。 Nanaomycins A和C通过在培养基中培养产生链霉菌属的链霉菌属的纳米霉素生产菌株在培养基中培养以在培养的肉汤中积累纳米菌素A和C而产生。 乙酰纳他霉素A和纳那霉素A甲酯的衍生物具有与纳那霉素A相似的性质。

    Production of nanaomycin A and derivatives thereof
    7.
    发明授权
    Production of nanaomycin A and derivatives thereof 失效
    生产纳诺霉素A及其衍生物

    公开(公告)号：US4196266A

    公开(公告)日：1980-04-01

    申请号：US858215

    申请日：1977-12-07

    申请人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    发明人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    IPC分类号： C12P17/06 ,  C12D9/14

    CPC分类号： C12R1/465 ,  C12P17/06 ,  Y10S435/886

    摘要： The present invention relates to new compound nanaomycin A and derivatives thereof represented by general formula: ##STR1## in which (a) R is H and R' is OH (nanaomycin A),(b) R is H and R' is NH.sub.2 (nanaomycin C),(c) R is COCH.sub.3 and R' is CH (acetylnanaomycin A), and(d) R is H and R' is OCH.sub.3 (nanaomycin A methyl ester).Nanaomycin A is a new compound of quinone type and its acute toxicity (LD.sub.50, intra-penetrial injection) in mice is 28.2 mg/Kg. Nanaomycin A and derivatives thereof are active on Gram-positive bacteria, trichophyton and mycoplasma and are useful as a medicament for humans and animals. Nanaomycins A and C are produced by culturing a nanaomycin-producing strain belonging to the genus Streptomyces aerobically in a medium to accumulate nanaomycins A and C in the cultured broths. The derivatives acetylnanaomycin A and nanaomycin A methyl ester have similar properties to those of nanaomycin A.

    摘要翻译： 本发明涉及由以下通式表示的新化合物纳那霉素A及其衍生物：其中（a）R是H，R'是OH（纳那霉素A），（b）R是H和R' 是NH2（纳那霉素C），（c）R是COCH 3，R'是CH（乙酰氨基霉素A），和（d）R是H，R'是OCH 3（纳诺霉素A甲酯）。 Nanaomycin A是醌类的新化合物，其在小鼠中的急性毒性（LD50，内渗注射）为28.2mg / Kg。 纳诺霉素A及其衍生物对革兰氏阳性菌，毛毛虫和支原体具有活性，可用作人和动物的药物。 Nanaomycins A和C通过在培养基中培养产生链霉菌属的链霉菌属的纳米霉素生产菌株在培养基中培养以在培养的肉汤中积累纳米菌素A和C而产生。 乙酰纳他霉素A和纳那霉素A甲酯的衍生物具有与纳那霉素A相似的性质。

    Production of nanaomycin B
    8.
    发明授权
    Production of nanaomycin B 失效
    生产纳诺霉素B

    公开(公告)号：US4194064A

    公开(公告)日：1980-03-18

    申请号：US858216

    申请日：1977-12-07

    申请人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    发明人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    IPC分类号： C12P17/06 ,  C12D9/14

    CPC分类号： C12R1/465 ,  C12P17/06 ,  Y10S435/886

    摘要： The present invention relates to new compound designated as nanaomycin B represented by general formula: ##STR1## Nanaomycin B is a quinone type and is active on mycoplasma, Gram-positive bacteria and trycophyton. This compound is useful as a medicament for infectious diseases of humans and animals caused by a parasite of trichophyton or mycoplasma etc. The acute toxicity (LD.sub.50, intra-penetrial injection) in mice of this compound is 169 mg/kg. Nanaomycin B is produced by fermentation in which a nanaomycin-producing strain belonging to the genus Streptomyces is cultured in a medium under aerobic conditions and the accumulated nanaomycin B in the cultured broths is recovered therefrom.

    摘要翻译： 本发明涉及以通式表示的纳那霉素B的新化合物：＆lt; IMAGE＆gt; Nanaomycin B是醌类，对支原体，革兰氏阳性菌和真菌是有活性的。 该化合物可用作由毛癣菌或支原体寄生虫等引起的人类和动物感染性疾病的药物。该化合物小鼠的急性毒性（LD50，内渗注射）为169mg / kg。 纳豆霉素B通过发酵生产，其中在需氧条件下培养在属于链霉菌属的纳米霉素生产菌株，并从其中回收培养肉汤中积累的纳诺霉素B.